Hemispherx Biopharma Reports Clinical Potential of Treatment for Drug-Resistant Influenza Virus - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Hemispherx Biopharma Reports Clinical Potential of Treatment for Drug-Resistant Influenza Virus


Hemispherx Biopharma published an article entitled “Emergence of a novel drug resistant H7N9 influenza virus: Evidence based clinical potential of a natural interferon (IFN)-αlpha for infection control and treatment” in the early online edition of Expert Review of Anti-infective Therapy, the company announced in a press release. H7N9 is a recently identified virus associated with high mortality in humans with the potential to emerge as an agent for a global pandemic. New cases of H7N9 have been recently reported in China, Hong Kong, and Taiwan. In vitro tests reported in the new article demonstrated that both oseltamivir (Tamiflu) and Alferon N have significant inhibitory effect on a neuraminidase-inhibitor sensitive H7N9 influenza virus. In contrast, Alferon N, but not Tamiflu, had an inhibitory effect on the neuraminidase-resistant Shanghai/1/H7N9 virus.

According to the peer-reviewed article, “Because of the lack of existing immunity against H7 subtype influenza viruses in the human population and the absence of a licensed commercial vaccine, antiviral drugs are critical tools for the treatment of infection with this novel H7N9. Both M2-ion channel blockers and neuraminidase inhibitors are used as antiviral drugs for influenza infections of humans. The emerging H7N9 viruses are resistant to the M2-ion channel blockers because of a S31N mutation in the M2 protein; additionally, some H7N9 isolates have gained neuraminidase R292K substitution resulting in broad resistance to neuraminidase inhibitors. In this study we report that Alferon N can inhibit wild type and 292K H7N9 viruses replication in vitro. Since Alferon N is approved for clinical use, this would allow a rapid regulatory approval process for this drug under pandemic threat.”

 

Source: Hemispherx Biopharma

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here